Program in Trauma, Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Neurocrit Care. 2022 Apr;36(2):463-470. doi: 10.1007/s12028-021-01323-z. Epub 2021 Aug 17.
Severe intracranial hypertension is strongly associated with mortality. Guidelines recommend medical management involving sedation, hyperosmotic agents, barbiturates, hypothermia, and surgical intervention. When these interventions are maximized or are contraindicated, refractory intracranial hypertension poses risk for herniation and death. We describe a novel intervention of verticalization for treating intracranial hypertension refractory to aggressive medical treatment.
This study was a single-center retrospective review of six cases of refractory intracranial hypertension in a tertiary care center. All patients were treated with a standard-of-care algorithm for lowering intracranial pressure (ICP) yet maintained an ICP greater than 20 mmHg. They were then treated with verticalization for at least 24 h. We compared the median ICP, the number of ICP spikes greater than 20 mmHg, and the percentage of ICP values greater than 20 mmHg in the 24 h before verticalization vs. after verticalization. We assessed the use of hyperosmotic therapies and any changes in the mean arterial pressure and cerebral perfusion pressure related with the intervention.
Five patients were admitted with subarachnoid hemorrhage and one with intracerebral hemorrhage. All patients had ICP monitoring by external ventricular drain. The median opening pressure was 30 mmHg (25th-75th interquartile range 22.5-30 mmHg). All patients demonstrated a reduction in ICP after verticalization, with a significant decrease in the median ICP (12 vs. 8 mmHg; p < 0.001), the number of ICP spikes (12 vs. 2; p < 0.01), and the percentage of ICP values greater than 20 mmHg (50% vs. 8.3%; p < 0.01). There was a decrease in total medical interventions after verticalization (79 vs. 41; p = 0.05) and a lower total therapy intensity level score after verticalization. The most common adverse effects included asymptomatic bradycardia (n = 3) and pressure wounds (n = 4).
Verticalization is an effective noninvasive intervention for lowering ICP in intracranial hypertension that is refractory to aggressive standard management and warrants further study.
严重的颅内高压与死亡率密切相关。指南建议采用镇静、高渗剂、巴比妥类药物、低温和手术干预等方法进行医学治疗。当这些干预措施达到最大化或存在禁忌时,难治性颅内高压会导致脑疝和死亡。我们描述了一种新的垂直化干预措施,用于治疗对强化药物治疗有抵抗的颅内高压。
这是一项在三级护理中心进行的难治性颅内高压单中心回顾性研究。所有患者均采用标准的降低颅内压(ICP)治疗方案,但 ICP 仍大于 20mmHg。然后,他们接受至少 24 小时的垂直化治疗。我们比较了垂直化前后 24 小时内 ICP 的中位数、大于 20mmHg 的 ICP 峰值数和大于 20mmHg 的 ICP 值百分比。我们评估了高渗治疗的使用情况,以及与干预相关的平均动脉压和脑灌注压的任何变化。
5 例患者因蛛网膜下腔出血入院,1 例因脑出血入院。所有患者均通过外部脑室引流进行 ICP 监测。中位开放压为 30mmHg(25-75 分位距 22.5-30mmHg)。所有患者在垂直化治疗后 ICP 均降低,ICP 中位数显著下降(12 对 8mmHg;p<0.001),ICP 峰值数减少(12 对 2;p<0.01),以及大于 20mmHg 的 ICP 值百分比降低(50%对 8.3%;p<0.01)。垂直化治疗后总的医疗干预减少(79 对 41;p=0.05),总的治疗强度评分降低。最常见的不良反应包括无症状心动过缓(n=3)和压疮(n=4)。
垂直化是一种有效的非侵入性干预措施,可降低强化标准治疗抵抗的颅内高压患者的 ICP,值得进一步研究。